RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Immunodiagnostic Systems Holdings - Stock

Immunodiagnostic Systems Holdings Revenue 2024

Immunodiagnostic Systems Holdings Revenue

39.35 M GBP

Ticker

IDH.L

ISIN

GB00B01YZ052

WKN

A0D9MS

In 2024, Immunodiagnostic Systems Holdings's sales reached 39.35 M GBP, a 2.17% difference from the 38.51 M GBP sales recorded in the previous year.

The Immunodiagnostic Systems Holdings Revenue history

YEARREVENUE (undefined GBP)GROSS MARGIN (%)
202039.3549,68
201938.5143,35
201837.9547,47
201740.0449,77
201638.3158,65
201545.3662,46
201452.2674,47
201349.7773,08
201253.6774,72
201150.1674,66
201037.1674,06
200924.9466,48
200818.6661,25
20079.9265,52
20068.1364,58
20055.4362,43
20044.4562,70

Immunodiagnostic Systems Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Immunodiagnostic Systems Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Immunodiagnostic Systems Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Immunodiagnostic Systems Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Immunodiagnostic Systems Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Immunodiagnostic Systems Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Immunodiagnostic Systems Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Immunodiagnostic Systems Holdings’s growth potential.

Immunodiagnostic Systems Holdings Revenue, Profit, and EBIT History

DateImmunodiagnostic Systems Holdings RevenueImmunodiagnostic Systems Holdings EBITImmunodiagnostic Systems Holdings Net Income
202039.35 M GBP1.33 M GBP3.35 M GBP
201938.51 M GBP340,000 GBP796,000 GBP
201837.95 M GBP1.46 M GBP1.23 M GBP
201740.04 M GBP3.06 M GBP3.01 M GBP
201638.31 M GBP466,000 GBP-32.17 M GBP
201545.36 M GBP4.25 M GBP2.35 M GBP
201452.26 M GBP10.12 M GBP6.95 M GBP
201349.77 M GBP11.27 M GBP7.8 M GBP
201253.67 M GBP12.41 M GBP4.74 M GBP
201150.16 M GBP17.13 M GBP12.99 M GBP
201037.16 M GBP11.28 M GBP8.08 M GBP
200924.94 M GBP5.37 M GBP4.82 M GBP
200818.66 M GBP4.28 M GBP2.84 M GBP
20079.92 M GBP2.21 M GBP1.59 M GBP
20068.13 M GBP1.25 M GBP920,000 GBP
20055.43 M GBP330,000 GBP210,000 GBP
20044.45 M GBP150,000 GBP-40,000 GBP

Immunodiagnostic Systems Holdings stock margins

The Immunodiagnostic Systems Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Immunodiagnostic Systems Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Immunodiagnostic Systems Holdings.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Immunodiagnostic Systems Holdings's sales revenue. A higher gross margin percentage indicates that the Immunodiagnostic Systems Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Immunodiagnostic Systems Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Immunodiagnostic Systems Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Immunodiagnostic Systems Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Immunodiagnostic Systems Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Immunodiagnostic Systems Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Immunodiagnostic Systems Holdings Margin History

Immunodiagnostic Systems Holdings Gross marginImmunodiagnostic Systems Holdings Profit marginImmunodiagnostic Systems Holdings EBIT marginImmunodiagnostic Systems Holdings Profit margin
202049.68 %3.38 %8.51 %
201943.35 %0.88 %2.07 %
201847.47 %3.85 %3.23 %
201749.77 %7.63 %7.52 %
201658.65 %1.22 %-83.98 %
201562.46 %9.36 %5.18 %
201474.47 %19.36 %13.3 %
201373.08 %22.64 %15.67 %
201274.72 %23.12 %8.83 %
201174.66 %34.15 %25.9 %
201074.06 %30.36 %21.74 %
200966.48 %21.53 %19.33 %
200861.25 %22.94 %15.22 %
200765.52 %22.28 %16.03 %
200664.58 %15.38 %11.32 %
200562.43 %6.08 %3.87 %
200462.7 %3.37 %-0.9 %

Immunodiagnostic Systems Holdings Aktienanalyse

What does Immunodiagnostic Systems Holdings do?

IDS, Immunodiagnostic Systems Holdings PLC, is an English-American diagnostic company that specializes in the development, manufacture, and marketing of diagnostic tests for various applications. The company was founded in 1977 in Boldon, England and is headquartered in Tyne and Wear. IDS started with a focus on researching enzyme immunoassays (EIA) and has expanded its offerings to include radioimmunoassays and chemiluminescent tests. IDS operates in sectors such as endocrinology, clinical chemistry, hematology, and oncology, and is known as a leading provider of diagnostic test kits in many countries. The company offers over 400 tests, including reagents, calibrators, controls, and devices for more than 200 different parameters. IDS sells its products through an international network of branches, distributors, and authorized dealers in Asia, Europe, North America, South America, and the Middle East. The company has also established subsidiaries in the US and China to expand its offerings and drive growth in these regions. IDS's business model is focused on meeting customer needs for reliable, accurate, and fast diagnostic solutions. The company adheres to the highest quality standards and is committed to the continuous development and improvement of its products to enhance patient care and laboratory work worldwide. IDS has made a name for itself in the diagnostic industry in recent years and is a pioneer in developing tests for emerging applications such as autoimmune diseases and food intolerances. The company invests heavily in research and development and collaborates closely with academic partners and research institutions to identify and develop innovative diagnostic solutions. In summary, IDS is a leading diagnostic company operating in various applications and offering a wide range of diagnostic test solutions. The company has experienced strong growth in recent years and is committed to expanding its product range and offerings to meet the needs of patients and laboratories worldwide. Immunodiagnostic Systems Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Immunodiagnostic Systems Holdings's Sales Figures

The sales figures of Immunodiagnostic Systems Holdings originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Immunodiagnostic Systems Holdings’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Immunodiagnostic Systems Holdings's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Immunodiagnostic Systems Holdings’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Immunodiagnostic Systems Holdings Stock

How much revenue did Immunodiagnostic Systems Holdings generate this year?

Immunodiagnostic Systems Holdings has achieved a revenue of 39.35 M GBP this year.

How much was the turnover of the company Immunodiagnostic Systems Holdings compared to the previous year?

The revenue of Immunodiagnostic Systems Holdings has increased by 2.17% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Immunodiagnostic Systems Holdings?

The revenue of Immunodiagnostic Systems Holdings is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Immunodiagnostic Systems Holdings measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Immunodiagnostic Systems Holdings so important for investors?

The revenue of Immunodiagnostic Systems Holdings is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Immunodiagnostic Systems Holdings pay?

Over the past 12 months, Immunodiagnostic Systems Holdings paid a dividend of 0.02 GBP . This corresponds to a dividend yield of about 50.26 %. For the coming 12 months, Immunodiagnostic Systems Holdings is expected to pay a dividend of 0.02 GBP.

What is the dividend yield of Immunodiagnostic Systems Holdings?

The current dividend yield of Immunodiagnostic Systems Holdings is 50.26 %.

When does Immunodiagnostic Systems Holdings pay dividends?

Immunodiagnostic Systems Holdings pays a quarterly dividend. This is distributed in the months of August, August, August, August.

How secure is the dividend of Immunodiagnostic Systems Holdings?

Immunodiagnostic Systems Holdings paid dividends every year for the past 15 years.

What is the dividend of Immunodiagnostic Systems Holdings?

For the upcoming 12 months, dividends amounting to 0.02 GBP are expected. This corresponds to a dividend yield of 50.26 %.

In which sector is Immunodiagnostic Systems Holdings located?

Immunodiagnostic Systems Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunodiagnostic Systems Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunodiagnostic Systems Holdings from 8/14/2020 amounting to 0.019 GBP, you needed to have the stock in your portfolio before the ex-date on 7/16/2020.

When did Immunodiagnostic Systems Holdings pay the last dividend?

The last dividend was paid out on 8/14/2020.

What was the dividend of Immunodiagnostic Systems Holdings in the year 2023?

In the year 2023, Immunodiagnostic Systems Holdings distributed 0.007 GBP as dividends.

In which currency does Immunodiagnostic Systems Holdings pay out the dividend?

The dividends of Immunodiagnostic Systems Holdings are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Immunodiagnostic Systems Holdings

Our stock analysis for Immunodiagnostic Systems Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immunodiagnostic Systems Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.